ClinicalTrials.gg
RecruitingNCT05740488Updated Mar 15, 2024

Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases

An interventional study of Apalutamide and 89Sr in Prostate Cancer With ≤10 Bone Metastases, sponsored by Zhujiang Hospital. Recruiting at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Zhujiang Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Jan 2022, registered Feb 2023).
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 487 studies in Neoplasm Metastasis with a site in China — 224 open to participants now, 264 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
311th of 403
30 · median 90
Started
2022
with 44 others
No phase
51 of 487
23 open now
Primary completion
2025-04
later than 39 of 263 live
Registered
266th of 487
by date

Among the 487 studies in Neoplasm Metastasis with a site in China, this one is the 311th largest by planned enrollment of the 403 interventional ones that give a count, is one of 45 that started in 2022, is one of 51 with no phase, reaches primary completion later than 39 of the 263 other live ones, and was the 266th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

224 of the 487 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

219 more — sign in →

All 224 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 487 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the efficacy and safety of apalutamide in combination with 89Sr as neoadjuvant therapy in prostate cancer with ≤10 bone metastases. The primary endpoint is PFS and the second endpoints are pCR, rPFS, PSA response, pain score, number and extent of bone metastases.

03

Conditions studied

  • Prostate Cancer With ≤10 Bone Metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prostate cancer confirmed by pathological findings;
  2. Bone confirmed by bone scan, the number of bone metastases ≤10
  3. Agreement to undergo laparoscopic radical prostatectomy + pelvic lymphadenectomy;
  4. score of 0 - 1
  5. Agreement to undergo preoperative and postoperative endocrine therapy and 89Sr radionuclide therapy;
  6. Voluntary signing of an ICF for the clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Any other tumor disease requiring treatment;
  2. Any organ confirmed by imaging, such as liver and , or the possibility of paralysis due to spinal cord metastasis;
  3. A history of epilepsy or any condition that may lead to seizures;
  4. Severe liver or kidney dysfunction, severe cardiovascular or cerebrovascular diseases, and systemic immune system diseases
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    apalutamide combined with 89Sr and ADT

    Neoadjuvant therapy with apalutamide in combination with 89Sr and ADT

    Drug: Apalutamide · Drug: 89Sr · Drug: Luteinizing Hormone-Releasing Hormone Analog

Interventions

06

What researchers measure

Primary outcomes

  1. PFS

    progression-free survival

    Time frame: Up to 2 years after radical prostatectomy

Secondary outcomes

  1. pCR

    pathological complete response

    Time frame: Up to 1 year

  2. rPFS

    radiographic progression-free survival

    Time frame: Up to 3 years

  3. PSA response rate

    more than 50% decrease from baseline

    Time frame: Up to 3 years

  4. pain score

    Measurement of pain assessed by a Visual Analogue Scale (VAS). The analogous visual scale used for this study measures from 0 to 10 the intensity of pain with a series of "faces" that show the intensity in the pain experimentation with categories such as "No pain" in number 0, mild in number 1-3, moderate in number 4-6, intense in number 7-9 and worst in number 10.

    Time frame: Measured at baseline and follow up visits throughout the study, an average of 3 years

  5. number and extent of bone metastases

    Bone Scan

    Time frame: Up to 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Apr 2025, 39 months after the start.

Of 295 non-industry interventional studies with no phase under Neoplasm Metastasis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 93. This study's planned 39 months is below that.

Counting every sponsor, half of 320 studies reached it within 54 months; a quarter within 28 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Feb 23, 2023
StartActual
Jan 7, 2022
Primary completionEst.
Apr 2025
CompletionEst.
Dec 2025
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05740488
Lead sponsor
Zhujiang Hospital
Responsible party
Binshen Chen (associate chief physician, Zhujiang Hospital) — Principal investigator
First posted
Feb 23, 2023
Start date
Jan 7, 2022
Primary completion
Apr 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Mar 15, 2024

Study contacts

Zhang Yiming
Contact
359281481@qq.com
020-62782726
Chen Binshen
study chair · Southern Medical University, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion